Letter: sitafloxacin for H. pylori infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|42|7|942-943

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.42, Iss.7, 2015-10, pp. : 942-943

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Letter: sitafloxacin for H. pylori infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm – author's reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 7, 2015-10 ,pp. : 943-944

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: clarithromycin dose for H. pylori therapy remains unresolved

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 5, 2015-09 ,pp. : 631-632

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: clarithromycin dose for H. pylori therapy remains unresolved – authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 5, 2015-09 ,pp. : 632-633

John Wiley & Sons Inc

Access to resources Recommend Favorite

High Helicobacter pylori cure rate with sitafloxacin‐based triple therapy

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 4, 2015-08 ,pp. : 477-483

John Wiley & Sons Inc

Access to resources Recommend Favorite

H. pylori Infection: Bacterial Virulence Factors and Cytokine Gene Polymorphisms as Determinants of Infection Outcome

By Basso Daniela   Plebani Mario  

Critical Reviews in Clinical Laboratory Sciences, Vol. 41, Iss. 3, 2004-01 ,pp. : 313-337

Informa Healthcare

Access to resources Recommend Favorite